Driving research of Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS),
Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia and Long Covid

$3 million pledge received for research!

$3 million pledged for new study at the Collaborative Research Center at Montréal!

#TripleGivingTuesday Research News

From the desk of Alain Moreau, PhD
Director of the Collaborative Research Center 
at the CHU Sainte-Justine/Université de Montréal

There is just one week left for #TripleGivingTuesday, OMF’s biggest fundraising campaign of the year. I’m excited to share amazing news on behalf of my research team at the ME/CFS Collaborative Research Center at the CHU Sainte-Justine / Université de Montréal: 

We just received a pledge of $1 million per year for three years from a group of anonymous Canadian donors to fund a new study entitled, “REMEDIAL: Precision Medicine for Myalgic Encephalomyelitis Drug Discovery and Clinical Trials.”

This exciting project has the potential to identify early intervention and targeted treatment strategies for persons with ME/CFS. We are incredibly grateful to our leadership donors for their investment in accelerating research!

The Project

The REMEDIAL project will provide a more comprehensive understanding as to why some ME/CFS patients exhibit different and distinct symptoms and how post-exertional malaise exacerbates many symptoms. Identifying specific biomarkers will aid in the development of risk prediction of complications associated with ME/CFS early prevention and better treatments.

Through our deep-phenotyping approach, we hope to understand the presentation, severity, and underlying causes of illness persistence. Working within the field of precision medicine, this study may lead to early intervention strategies and targeted treatment approaches by repositioning drugs currently used for other clinical applications. Precision medicine is essential to address the clinical complexity of ME/CFS and to identify the best therapeutic options to treat the disease. 

What does this mean for people with ME/CFS?

The findings from this project will lead to a better understanding of the molecular mechanisms underlying ME/CFS development, the persistence and variability of the symptoms, and the identification of potential treatment targets for intervention.

Stay tuned for more information as this project is rolled out. 

*While OMF funds research projects at our six established Collaborative Research Centers, we are not typically involved in the research process and cannot introduce constituents to researchers. CRCs are not able to respond to inquiries from the general public. When OMF seeks participants in any data gathering research project, we will email those requests to our entire community. *

We are so thankful for the generosity and trust of our anonymous donors. Their investment in this groundbreaking initiative is what will bring us closer to finding treatments and a cure for millions who’ve been suffering from ME/CFS for far too long.

Please consider making your own investment in research by donating to #TripleGivingTuesday before it’s over! With just one week left in the campaign, NOW is the time to donate and have your gift triple matched! 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

What are the advantages of giving from your Donor Advised Fund (DAF)?

  • Your gifts to your donor advised fund entitle you to an immediate income tax deduction at the time of contribution.
  • You avoid capital gains tax on appreciated assets you place in your donor advised fund.
  • Your fund’s investment gains accumulate tax free.
  • Funds are distributed to Open Medicine Foundation in your name and immediately put to use to support our worldwide research efforts.

How do I make a donation through my DAF?

Just click on the DAF widget below. It is simple and convenient to find your fund among the over 900 funds in our system.

Still can’t find your fund? 

  • Request a grant distribution through your Donor Advised Fund sponsor
  • Be sure to use OMF’s EIN #26-4712664
  • You can also designate OMF as a beneficiary for your Donor Advised Fund
  • Questions? Give us a call at 650-242-8669 
 

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome (ME / CFS) Post Treatment Lyme Disease Syndrome (PTLDS), Fibromyalgia Leading Research. Delivering Hope.Open Medicine Foundation®

Averting a second pandemic:

Open Medicine Foundation leads groundbreaking international study of

Long COVID’s conversion to ME/CFS

AGOURA HILLS, CALIF.  — Open Medicine Foundation (OMF) is leading a large-scale international collaborative study investigating the potential conversion of Post-Acute Sequelae SARS-CoV-2 infection — more commonly known as Long COVID or Post-COVID Syndrome —  to Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a chronic, life-altering disease with no known cause, diagnostic test or FDA approved treatments available.

Up to 2.5 million people in the U.S. alone suffer from ME/CFS; the COVID-19 pandemic could at least double that number. An estimated 35 percent of Americans who had COVID-19 have failed to fully recover several months after infection, prompting many to call it “a potential second pandemic.”

OMF recognized a familiar health crisis emerging, one with eerie similarities to ME/CFS. This crisis presented a unique opportunity to understand how a viral infection — in this case COVID-19 — may develop into ME/CFS in some patients. The goal is to find targeted treatments for ME/CFS patients and ultimately prevent its onset in people infected with SARS-CoV-2 or other infections.

The federal government is only now investing in Post-COVID research, with no focus on its connection to ME/CFS. OMF has already engaged researchers for the largest-scale study of its kind, solely supported by private donors who have contributed over one million dollars to date. When fully funded, the five million dollar, three-year study will be conducted across the globe at OMF funded Collaborative Research Centers, led by some of the world’s top researchers and ME/CFS experts.

BACKGROUND

In a significant percentage of patients, infections preceded their development of ME/CFS.  For example, according to the CDC about one in ten infected with Epstein-Barr virus, Ross River virus, or Coxiella burnetti develop symptoms that meet the criteria for ME/CFS.

THE STUDY

The ability to follow the development of ME/CFS from a known viral infection is unprecedented to date and crucial to researchers’ understanding of the disease. The focus of this study is to find the biological differences between persons returning to good health after COVID-19 and persons who remained ill more than six months after infection and developed ME/CFS.  Understanding these alterations in key pathways can lead to groundbreaking discoveries including new biomarkers, drug targets, and prevention and treatment strategies.

###

About Open Medicine Foundation

Established in 2012, Open Medicine Foundation leads the largest, concerted worldwide nonprofit effort to diagnose, treat, and prevent ME/CFS and related chronic, complex diseases such as Post Treatment Lyme Disease Syndrome, Fibromyalgia, and Post COVID. OMF adds urgency to the search for answers by driving transformational philanthropy into global research. We have raised over $28 Million from private donors and facilitated and funded the establishment of six prestigious ME/CFS Collaborative Research Centers around the world. To learn more, visit www.omf.ngo.

CONTACT:

Heather Ah San

Development and Communications Manager

1-650-242-8669

heather@omf.ngo